# Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

- Link: https://www.thailand-business-news.com/pr-news/diagens-annual-results-100b-parameter-model-reshapes-medical-ai-landscape-licensing-revenue-becomes-primary-growth-engine
- Published: 2026-04-30T12:18:00+07:00
- Author: PR Newswire

HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ — Hangzhou Diagens Biotech
Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models,
today announced its first annual results since its listing. The report marks a pivotal
milestone in the company’s transition from technical validation to large-scale commercialization,
with annual revenue reaching RMB 164 million, a year-on-year increase of 133.7%.

Driven by the rapid adoption of its proprietary iMedImage^(®) foundation model, 
Diagens saw its technology licensing revenue soar by 331.7% to RMB 84.34 million,
officially becoming the company’s primary growth engine. Gross profit reached RMB
118 million, with a robust margin of 71.8%, reflecting a high-value business model
built on "Model-as-a-Service" (MaaS).

**The Industrialization of Medical AI: From "Bespoke Projects" to "Mass Production"**

The medical imaging sector accounts for approximately 80% of global clinical data,
yet traditional AI has long struggled with "point solutions"—developing one model
for one disease in a single modality. This fragmented approach results in long R&
D cycles and high costs, covering only a tiny fraction of the thousands of potential
clinical applications.

Diagens is disrupting this legacy paradigm. Its iMedImage^(®) foundation model, 
boasting 104 billion parameters, covers 19 imaging modalities and 26 clinical specialties.
By providing a standardized technological bedrock, Diagens has reduced the cost 
and time of developing high-quality specialized models by over 90%.

[⌊Pipeline of Diagens’ biotechnology products and development programs⌉⌊Pipeline
of Diagens’ biotechnology products and development programs⌉[
Pipeline of Diagens’
biotechnology products and development programs

"We are witnessing a systemic restructuring of clinical capabilities," said a representative
of Diagens’ cross-disciplinary expert team, which comprises veterans from basic 
medicine, clinical practice, and advanced AI. "Our goal is to break the cost-efficiency
barrier of medical AI, moving from ‘craftsman-style’ development to an industrial-
scale deployment that can fill the widening global gap in healthcare resources."

**MaaS Ecosystem: Accelerating Global Healthcare Infrastructure**

Within just six months of launching the iMed MaaS^(®) (Model-as-a-Service) platform
in 2025, Diagens partnered with 65 top-tier hospitals to incubate 92 specialized
models. This ecosystem allows healthcare institutions to rapidly deploy AI capabilities
tailored to specific clinical needs, effectively turning sophisticated diagnostic
expertise into a scalable digital utility.

Diagens’ reach now extends to over 400 medical institutions across China, including
adoption by 40% of the nation’s top ten hospitals. Beyond China, the company is 
positioning itself as a global healthcare AI infrastructure provider, aiming to 
lower the threshold for high-quality diagnostics worldwide.

**Strategic Outlook: Scaling the New Productive Force**

Looking ahead, Diagens plans to deepen its strategic collaboration with ecosystem
partners, including technology giants like Tencent, to build a "Device + Service
+ Data" hub. By integrating the iMedImage^(®) foundation model into the global healthcare
value chain, Diagens seeks to address the existential challenges of aging populations
and physician shortages.

"This is not just a leap in tool efficiency; it is a fundamental shift in how medical
services are produced and delivered," stated Dr. Ning Song, Chairman of Diagens."
Standing at this historical inflection point, we are committed to working with global
stakeholders to ensure that truly clinical-grade AI is accessible, reliable, and
safe for every patient, everywhere."

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine ](http://www.prnasia.com/story/archive/4947731_AE47731_0?rand=184833)